Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy

Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the management of relapsed and refractory myeloma, with excellent outcomes and a tolerable safety profile. High dose chemotherapy with autologous hematopoietic stem cell transplantation (AHCT) is established as a mainstream of newly d...

Full description

Bibliographic Details
Main Authors:	Charlotte F. M. Hughes, Gunjan L. Shah, Barry A. Paul
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Series:	Frontiers in Oncology
Subjects:	autologous transplant CAR T cell therapy multiple myeloma newly diagnosed multiple myeloma relapsed refractory multiple myeloma
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1373548/full

Similar Items

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
by: Dima D, et al.
Published: (2020-08-01)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
by: Massimo Offidani, et al.
Published: (2021-02-01)

Risk Assessment for Newly Diagnosed Fit Young Patients with Multiple Myeloma in the Era of Novel Treatment Modalities: Should There Be Additional Factors Taken into Consideration??
by: Kaloyannidis P, et al.
Published: (2022-10-01)

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

Allogeneic stem cell transplantation in multiple myeloma: is there still a place?
by: Carmine Liberatore, et al.
Published: (2024-06-01)

Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma
by: Chutima Kunacheewa, et al.
Published: (2021-04-01)

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
by: Ja Min Byun, et al.
Published: (2022-10-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01)

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
by: Zoe van de Wyngaert, et al.
Published: (2023-02-01)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
by: Francesca Fazio, et al.
Published: (2022-02-01)

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
by: Bhutani D, et al.
Published: (2017-07-01)

Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma
by: Juan José Gil‐Fernández, et al.
Published: (2024-01-01)

Double Autologous Stem Cell Transplantation in a Case of Non-secretory Multiple Myeloma
by: Lázár Erzsébet, et al.
Published: (2016-12-01)

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
by: Yimei Que, et al.
Published: (2021-10-01)

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
by: Fevzi Fırat Yalnız, et al.
Published: (2017-08-01)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
by: Gils Roex, et al.
Published: (2020-12-01)

Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-year Experience from a Single Centre in North India
by: Nitin Sood, et al.
Published: (2023-04-01)

A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
by: Wee-Joo Chng, et al.
Published: (2024-11-01)

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy
by: Goel U, et al.
Published: (2025-02-01)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
by: Samer A. Srour, et al.
Published: (2021-08-01)

Survival and response deepening after autologous transplantation in patients with multiple myeloma in Chile
by: María Carolina Guerra, et al.
Published: (2022-12-01)

Recombinant human thrombopoietin does not promote platelet engraftment in newly diagnosed multiple myeloma patients following autologous stem cell transplantation
by: Ruiqi Wang, et al.
Published: (2025-02-01)

CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
by: Tong Yu, et al.
Published: (2025-02-01)

Prognostic Impact on Survival of Early Relapse after Autologous Stem Cell Transplantation with Non-cryopreserved Stem Cells for Multiple Myeloma in Real Life: A Single-center Cohort Study from Oran (Algeria)
by: Mohamed Amine Bekadja, et al.
Published: (2022-02-01)

Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
by: Huixing Zhou, et al.
Published: (2023-04-01)

Autologous hematopoietic transplantation following COVID‐19 infection
by: Marthilde Brzycki, et al.
Published: (2021-03-01)

Autologous Hematopoietic Cell Transplant as an Effective Treatment Modality for Systemic Sclerosis and Multiple Myeloma
by: Memon H, et al.
Published: (2025-01-01)

Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review
by: Tung-Lung Yang, et al.
Published: (2023-11-01)

CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy?
by: Paula Rodriguez-Otero, et al.
Published: (2024-05-01)

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
by: Wan-Hong Zhao, et al.
Published: (2018-12-01)

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
by: Chunrui Li, et al.
Published: (2021-03-01)

CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
by: Rendo MJ, et al.
Published: (2022-08-01)

Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments
by: Luca Cancanelli, et al.
Published: (2023-01-01)

UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
by: Patrizia Tosi, et al.
Published: (2012-01-01)

UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
by: Patrizia Tosi, et al.
Published: (2012-11-01)

Single-Cell Transcriptomes Combining with Consecutive Genomics Reveal Clonal Evolution and Gene Regulatory Networks in Relapsed and Refractory Multiple Myeloma
by: Jiadai Xu, et al.
Published: (2022-01-01)

Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
by: Malkan Umit Yavuz, et al.
Published: (2021-01-01)

Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis
by: Hongtao Li, et al.
Published: (2024-12-01)

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
by: Arleigh McCurdy, et al.
Published: (2022-03-01)